Tonix is a clinical-stage biopharmaceutical company focused on bringing novel therapeutics and diagnostics to prevent and treat infectious diseases, central nervous system disorders and immunology conditions. At Tonix, we are focused on identifying and developing candidates that have the promise to treat and prevent human disease and alleviate suffering. Through our own development, in-licensing, collaborations and acquisitions we are curating an innovative and effective portfolio that targets the relief of pain, and attenuates infection. Currently, our pipeline is primarily comprised of infectious disease, central nervous system (CNS) and immunology product candidates. Our infectious disease portfolio includes COVID-19 next-generation vaccines to prevent COVID-19, an antiviral to treat COVID-19, and a potential treatment for Long COVID. We are progressing small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions through our CNS portfolio. Finally, our immunology portfolio includes biologics to address immunosuppression, cancer, and autoimmune diseases.